Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arcatus
- Development stage
- Unknown
- Lead developer
- Clearside Biomedical
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic, Suprachoroidal
01
Overview
Arcatus is a proprietary injectable suspension of the corticosteroid triamcinolone acetonide, formulated for administration to the suprachoroidal space of the eye. It is indicated for the treatment of macular edema associated with non-infectious uveitis (uveitic macular edema, UME). The drug utilizes an innovative delivery platform—suprachoroidal space microinjection (SCS Microinjector)—which enables targeted delivery to the back of the eye, potentially enhancing efficacy and minimizing adverse effects compared to traditional local corticosteroid therapies. Triamcinolone acetonide acts as a potent anti-inflammatory glucocorticoid by modulating gene expression and suppressing inflammatory mediators. Arcatus is known as Xipere in the United States and has been approved or submitted for approval in multiple regions including China, Australia, Singapore, and others[1][5][6][7].
- Brand names
- Arcatus
- Other names
- Xipere锋脉
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Arcatus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arcatus.